Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15610599 | 0.85 | MEN1 (0.38) | GAAHTT | |
| SCHEMBL4112434 | 0.81 | RIPK1 (0.37) | CYP3A4 | |
| SCHEMBL12509911 | 0.78 | CLCN2 (0.33) | CLCN2 | |
| SCHEMBL147397 | 0.76 | LMNA (0.36) | ALDH1A1GAAHTT | |
| SCHEMBL5672566 | 0.76 | PYCR1 (0.35) | ALDH1A1 | |
| SCHEMBL6298659 | 0.75 | PYCR1 (0.35) | ALDH1A1 | |
| SCHEMBL12425646 | 0.74 | LMNA (0.39) | ALDH1A1GAAHTT | |
| SCHEMBL14126456 | 0.72 | NQO2 (0.35) | ALDH1A1GAA | |
| SCHEMBL5672882 | 0.72 | SMN1; SMN2 (0.35) | ALDH1A1HTT | |
| SCHEMBL31185675 | 0.72 | SLC6A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | CLCN2 369/4885CYP1A2 1601/4885CYP3A4 2688/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | CLCN2 369/4885CYP1A2 1601/4885CYP3A4 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.